ClinicalTrials.gov
public full text
Public Domain
A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)
This is a Phase III randomized, double-blind, parallel group, multi-center, 52-week COPD exacerbation and lung function study with PT009 320/9.6 μg, PT009 160/9.6 μg and PT005 9.6 μg, all administered BID.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).#886859
- Nurse-led Integrated Care in COPD Patients With a Pulmonary Exacerbation#1093895
- Untargeted Screening of Environmental and Endogenous Metabolites and Risk of Incident COPD: A Prospective Study in Three European Populations#398620
- Untargeted Screening of Environmental and Endogenous Metabolites and Risk of Incident COPD: A Prospective Study in Three European Populations#130509
- Untargeted Screening of Environmental and Endogenous Metabolites and Risk of Incident COPD: A Prospective Study in Three European Populations#68016
Record · ID 858978
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive